Multiple%20myeloma News

News

Idecabtagene vicleucel boosts PFS and responses vs standard regimens in triple class–exposed R/R MM

Christina Lau, 20230417000000

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.

Original New Drug Application Approvals by US FDA (16 - 31 October 2022)

20221102095557

New drug applications approved by US FDA as of 16 - 31 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Teclistamab demonstrates clinical activity for R/R MM

Audrey Abella, 20220811100000

The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

20220731000000

New drug applications approved by US FDA as of 16 - 31 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Upfront ASCT + RVd improves PFS in NDMM

Roshini Claire Anthony, 20220716110001

Upfront autologous stem cell transplantation (ASCT) plus lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), results of the phase III DETERMINATION trial showed.

Post-transplant KRd a new SoC for MM?

Audrey Abella, 20220707100000

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

$Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma$

Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma

20220608180000

Ixazomib-dexamethasone (ixa-dex) and pomalidomide-dexamethasone (pom-dex) achieve comparable levels of efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients who had already been exposed to prior lenalidomide-based regimens, a recent study has found.

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

20220531000000

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Accelerated daratumumab infusion safe, well tolerated in multiple myeloma

20220529120000

Accelerated administration of daratumumab, an anti-CD3 monoclonal antibody approved for multiple myeloma, is safe and well tolerated when given following at least two standard infusions, suggest the results of a recent study.

High BMI might promote MGUS progression to multiple myeloma

20220517180000

In individuals with monoclonal gammopathy of undetermined significance (MGUS), obesity or high body mass index (BMI) seems to aggravate the risk of disease progression to multiple myeloma (MM), an effect that appears to be stronger in women, a recent study has found.

Comprehensive genomic profiling in oncology – from vision to reality

Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019

Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.